Showing 1251-1260 of 7668 results for "".
- No Antibiotics Needed For Mild Infected Eczema in Kidshttps://practicaldermatology.com/news/no-antibiotics-needed-for-mild-infected-eczema-in-kids/2458238/Oral or topical antibiotics are not effective for treating milder clinically infected eczema in children, a new study shows. In the study of 113 children with clinical, non-severely infected eczema, participants received either oral and topical placebos (control), oral antibiotic (flucloxacillin) …
- 5α-Reductase Inhibitors Not Associated with Increased Suicide Risk in Older Menhttps://practicaldermatology.com/news/5-reductase-inhibitors-not-associated-with-increased-suicide-risk-in-older-men/2458240/Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men, according to new research in JAMA Internal Medicine. Risks for self-harm and depression were increased during the 18 months after medication initiation, although “the relatively small magnitude o…
- ADAM Names Lori Skraba 2017 Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-names-lori-skraba-2017-practice-manager-of-the-year/2458248/The Association of Dermatology Administrators and Managers (ADAM) named Lori Skraba of DuBois Dermatology and Cosmetics in DuBois, Pa., the recipient of the annual Practice Manager of the Year award. She was recognized at the 25th annual ADAM meeting in Orlando, FL. The ADAM Practice Manager of th…
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.https://practicaldermatology.com/news/pershing-square-capital-management-lp-announces-sale-of-its-investment-in-valeant-pharmaceuticals-international-inc/2458249/Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the Valeant board until the upc…
- Survey Findings: Submental Region Major Pain Point for Patientshttps://practicaldermatology.com/news/survey-findings-submental-region-major-pain-point-for-patients/2458247/Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc. The findings were presented at the American Academy of Dermatology (AAD) Meeting in Orlando, FL. The n…
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key secondary endpoints. There are no currently approved treatments for prurigo nodular…
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error associated with new immu…
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annual Meetin…
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill vi…
- Zeltiq Shines Spotlight on CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://practicaldermatology.com/news/zeltiq-shines-spotlight-on-coolmini-applicator-at-aad-annual-meeting/2458259/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the Food and Drug Administration (FDA) to address the upper arm. “A…